The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.
BMP-6 and retinoic acid synergistically differentiate the IMR-32 human neuroblastoma cells.
BACKGROUND: We studied the effects of all-trans retinoic acid (ATRA) and Bone morphogenetic protein-6 (BMP-60 on neuronal differentiation of IMR-32 cells. MATERIALS AND METHODS: Immunostaining, Western blotting and MTT assays were used to characterize the survival and neuronal phenotype of IMR-32 cells differentiated by ATRA +/- BMP-6. RESULTS & CONCLUSION: ATRA, BMP-6 and ATRA + BMP-6 treatments each induced dopaminergic neuronal differentiation of the IMR-32 cells as judged by expression of GAP-43, tyrosine hydroxylase and microtubule-associated protein 2ab. ATRA alone induced strong biochemical differentiation, whereas ATRA + BMP-6 treatment synergistically enhanced neurite outgrowth and morphological maturation. When compared with undifferentiated controls, ATRA induced Bcl-2 expression, while loss of Bax expression was observed only in cells differentiated by ATRA + BMP-6. The high Bcl-2/Bax ratio in cells differentiated by ATRA and ATRA + BMP-6, respectively, correlated with the survival of these cells in serum-free media. Upon re-exposure to fresh serum lacking factors, only cells differentiated by ATRA + BMP-6 were unable to resume cell division. In concordance with their morphological maturation, these cells were terminally differentiated when compared with cells differentiated by separate treatment with ATRA or BMP-6.[1]References
- BMP-6 and retinoic acid synergistically differentiate the IMR-32 human neuroblastoma cells. Sumantran, V.N., Brederlau, A., Funa, K. Anticancer Res. (2003)
